Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis
- 684 Downloads
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world, affecting about 1/3 of the US general population and remaining as a significant cause of morbidity and mortality. The hallmark of the disease is the excessive accumulation of fat within the liver cells (hepatocytes), which eventually paves the way to cellular stress, injury and apoptosis. NAFLD is strongly associated with components of the metabolic syndrome and is fast emerging as a leading cause of liver transplant in the USA. Based on clinico-pathologic classification, NAFLD may present as isolated lipid collection (steatosis) within the hepatocytes (referred to as non-alcoholic fatty liver; NAFL); or as the more aggressive phenotype (known as non-alcoholic steatohepatitis; NASH). There are currently no regulatory agency- approved medication for NAFLD, despite the enormous work and resources that have gone into the study of this condition. Therefore, there remains a huge unmet need in developing and utilizing pre-clinical models that will recapitulate the disease condition in humans. In line with progress being made in developing appropriate disease models, this review highlights the cutting-edge preclinical in vitro and animal models that try to recapitulate the human disease pathophysiology and/or clinical manifestations.
KeywordsNon-alcoholic fatty liver disease (NAFLD) Non-alcoholic steatohepatitis (NASH) Organotypic liver system Lipitoxic system Diet induced animal model of non-alcoholic fatty liver disease (DIAMOND) Farnesoid X receptor (FXR)
Support: RO1 DK 105961 (National Institute of Diabetes and Digestive and Kidney Diseases). T32 DK007150/DK/NIDDK NIH HHS/United States [National Institute of Diabetes and Digestive and Kidney Diseases (US)]. R44 DK115301 (SBIR, HemoShear Therapeutics).
Compliance with ethical standards
Conflict of interest
Abdul M. Oseini, MD No conflicts to disclose, Danny Issa, MD No conflicts to disclose, Ryan E. Feaver, PhD Employee of HemoShear, Banumathi K. Cole, PhD Employee of HemoShear. Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, Exhalenz and Hemoshear. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Jannsen and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Novo Nordisk, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate.
- 11.Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9(6):524. https://doi.org/10.1016/j.cgh.2011.03.020.CrossRefPubMedGoogle Scholar
- 12.European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59(6):1121–40. https://doi.org/10.1007/s00125-016-3902-y.
- 13.Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop. Hepatology 2015;61(4):1392–405. https://doi.org/10.1002/hep.27678.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, Zhong XB. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 2010;38(6):988–94. https://doi.org/10.1124/dmd.109.031831.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Rodriguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32(6):505–20. https://doi.org/10.1080/00498250210128675.CrossRefPubMedGoogle Scholar
- 30.Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150(5):1147–1159. https://doi.org/10.1053/j.gastro.2016.01.038.CrossRefPubMedGoogle Scholar
- 34.Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385(9972):956–65. https://doi.org/10.1016/S0140-6736(14)61933-4.CrossRefPubMedGoogle Scholar
- 38.Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 2016;11:451–96. https://doi.org/10.1146/annurev-pathol-012615-044224.CrossRefPubMedGoogle Scholar
- 39.Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295(5):G987–95. https://doi.org/10.1152/ajpgi.90272.2008.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301(5):G825–34. https://doi.org/10.1152/ajpgi.00145.2011.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 2013;268(1):1–16. https://doi.org/10.1016/j.taap.2013.01.012.CrossRefPubMedGoogle Scholar
- 50.Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS ONE 2016;11(7):e0158674. https://doi.org/10.1371/journal.pone.0158674.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, et al. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 2015;43(7):1091–9. https://doi.org/10.1124/dmd.115.063495.CrossRefPubMedPubMedCentralGoogle Scholar